Amrita Singh C.
About Amrita Singh C.
Amrita Singh C. is a Senior Research Investigator at Roivant Sciences, specializing in high-throughput screening for targeted protein degradation. She has a Ph.D. in Biochemistry & Molecular Biology from the University of Calgary and has previously worked at Harvard Medical School and FogPharma.
Current Role at Roivant Sciences
Amrita Singh C. serves as a Senior Research Investigator at Roivant Sciences, a position she has held since 2022. In this role, she focuses on developing high-throughput screening amenable assays for targeted protein degradation. Her work contributes to advancing research initiatives within the organization, leveraging her expertise in biochemistry and molecular biology.
Previous Experience at FogPharma
Prior to her current role, Amrita worked as a Scientist II at FogPharma from 2019 to 2021. During her tenure, she developed high-throughput mass spectrometry and cell-based platforms for screening active cell penetrable mini proteins and peptide permeability. She collaborated with various departments, including Chemical Biology and Chemistry, to achieve research objectives.
Postdoctoral Fellowship at Harvard Medical School
Amrita completed a postdoctoral fellowship at Harvard Medical School, specifically at the Dana Farber Cancer Institute, from 2017 to 2019. This two-year experience in Boston, USA, allowed her to further her research skills and contribute to significant projects in cancer research.
Educational Background in Biochemistry and Biotechnology
Amrita Singh C. earned her Doctor of Philosophy (Ph.D.) in Biochemistry & Molecular Biology from the University of Calgary, where she studied from 2010 to 2016. Prior to this, she obtained a B.Sc. Honors in Biotechnology from Manipal Academy of Higher Education, studying from 2006 to 2010. Her educational background provides a strong foundation for her research career.
Research Contributions and Publications
Amrita is a co-first author of a research paper published in Cell Reports in 2020, which focuses on KRAS G12C signaling in pancreatic and lung cancers. This publication highlights her contributions to the field of cancer research and her ability to collaborate effectively on significant scientific inquiries.